

Therapeutic effects of KCC2 chloride transporter activation on detrusor overactivity in mice with spinal cord injury

メタデータ	言語: en 出版者: American Physiological Society 公開日: 2024-03-15 キーワード (Ja): キーワード (En): 作成者: 渡邊, 恭平 メールアドレス: 所属:
URL	http://hdl.handle.net/10271/0002000113

1 **Therapeutic effects of KCC2 chloride transporter activation on detrusor**
2 **overactivity in mice with spinal cord injury**

3

4 Kyohei Watanabe¹⁾²⁾, Masaru Ishibashi¹⁾, Takahisa Suzuki³⁾⁴⁾, Atsushi Otsuka²⁾,
5 Naoki Yoshimura⁵⁾, Hideaki Miyake²⁾, and Atsuo Fukuda¹⁾

6

7 1 Department of Neurophysiology, Hamamatsu University School of Medicine,
8 Hamamatsu, Japan

9 2 Department of Urology, Hamamatsu University School of Medicine,
10 Hamamatsu, Japan

11 3 Department of Urology, Kanagawa Rehabilitation Hospital, Atsugi, Japan

12 4 Department of Urology, Yokohama City University, Yokohama, Japan

13 5 Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh,
14 PA, USA

15

16

17 Correspondence: Atsuo Fukuda, M.D., Ph.D.

18 Department of Neurophysiology, Hamamatsu University School of Medicine,
19 Hamamatsu, Japan

20 1-20-1 Handayama, Higashi-Ku, Hamamatsu, Japan 431-3192

21 Tel.: +81-53-435-2246, Fax: +81-53-435-2245

22 E-mail: axfukuda@hama-med.ac.jp

23

24

25

26 **Running Title**

27 KCC2 DOWNREGULATION AND DETRUSOR OVERACTIVITY IN SCI MICE

28

29

30 **ABSTRACT**

31 This study aimed to clarify whether the down regulation of K⁺-Cl⁻-co-transporter
32 2 (KCC2) in the sacral parasympathetic nucleus (SPN) of the lumbosacral spinal
33 cord, from which the efferent pathway innervating the bladder originates, causes
34 cellular hyperexcitability and triggers detrusor overactivity (DO) in spinal cord
35 injury (SCI). SCI was produced by the Th8-9 spinal cord transection in female
36 C57BL/6 mice. At 4 weeks after SCI, CLP290, a KCC2 activator, was
37 administered, and cystometry was performed. Thereafter, neuronal activity with
38 c-fos staining and KCC2 expression in the cholinergic preganglionic
39 parasympathetic neurons in the SPN were examined using
40 immunohistochemistry. Firing properties of neurons in the SPN region were
41 evaluated by extracellular recordings in spinal cord slice preparations. DO
42 evident as non-voiding contractions (NVC) was significantly reduced by CLP290
43 treatment in SCI mice. The number of c-fos-positive cells and co-expression of
44 c-fos in choline acetyltransferase (ChAT)-positive cells were decreased in the
45 SPN region of SCI-CLP290 group vs. SCI-vehicle group. KCC2
46 immunoreactivity was present on the cell membrane of SPN neurons, and the
47 normalized fluorescence intensity of KCC2 in ChAT-positive SPN neurons was
48 decreased in SCI-vehicle group, vs. SI-vehicle group, but recovered in
49 SCI-CLP290 group. Extracellular recordings showed that CLP290 suppressed
50 the high frequency firing activity of SPN neurons in SCI mice. These results
51 indicated that SCI-induced DO is associated with downregulation of KCC2 in
52 preganglionic parasympathetic neurons, and that activation of KCC2
53 transporters can reduce DO, increase KCC2 expression in preganglionic
54 parasympathetic neurons and decrease neuronal firing of SPN neurons in SCI
55 mice.

56

57

58 **NEW & NOTEWORTHY**

59 This study is the first report to suggest that activation of KCC2 chloride ion

60 transporter may be a therapeutic modality for the treatment of SCI-induced DO
61 by targeting bladder efferent pathways.

62

63 Key words: KCC2, detrusor overactivity, efferent nerve, sacral parasympathetic
64 nucleus, spinal cord injury

65

66 Abbreviations:

67 BDNF: brain-derived neurotropic factor

68 ChAT: choline acetyltransferase

69 DO: detrusor overactivity

70 DCM: dorsal commissure

71 GABA: gamma-aminobutyric acid

72 ICI: intercontraction interval

73 IHC: immunohistochemistry

74 IVBP: intravesical baseline pressure

75 KCC2: K⁺-Cl⁻ co-transporter2

76 LDH: lateral dorsal horn

77 LUTD: lower urinary tract dysfunction

78 MCP: maximum voiding bladder contraction pressure

79 MDH: medial dorsal horn

80 NVCs: Non-voiding contractions

81 OAB: overactive bladder

82 PVR: post-void residual urine volume

83 QOL: quality of life

84 SCI: spinal cord injury

85 SI: spinal intact

86 SPN: sacral parasympathetic nucleus

87

88

89 **INTRODUCTION**

90

91 Overactive bladder (OAB) is generally characterized by frequent urination,
92 urgency, and urge urinary incontinence, that impairs quality of life [1]. The main
93 mechanism underlying the pathophysiology of OAB is detrusor overactivity (DO),
94 which produces involuntary contractions of the detrusor muscles during the urine
95 storage phase [2].

96 The functions of the lower urinary tract depend on the coordination of neural
97 circuits in the brain, spinal cord, and peripheral nervous system, and several
98 neurotransmitters play important roles in the control of these functions [3]. Spinal
99 cord injury (SCI) above the sacral level has been identified as one of the major
100 disorders inducing lower urinary tract dysfunction (LUTD), including DO [4].
101 Although various mechanisms have been reported for SCI-induced DO, previous
102 studies showed that gamma-aminobutyric acid (GABA) and glycine, two major
103 inhibitory neurotransmitters in the central nervous system (CNS), were
104 down-regulated in the lumbosacral spinal cord after SCI, as evidenced by the
105 reduced expressions of the GABA-synthesizing enzyme, glutamic acid
106 decarboxylase (GAD) [5] and glycine [6], respectively.

107 Furthermore, GABA generally exerts inhibitory effects in the CNS, including the
108 spinal cord; however, it may also act as an excitatory transmitter in immature
109 cells or under pathological conditions, such as injury [7][8][9]. This paradoxical
110 signaling of GABA is dependent on the intracellular Cl^- concentration in neurons.
111 K^+ - Cl^- -co-transporter 2 (KCC2) is specifically expressed in nerve cells, and
112 maintains a low intracellular Cl^- concentration by pumping K^+ and Cl^- ions out of
113 the cell [10]. Therefore, when KCC2 levels are low, for example, during the
114 developmental phase, intracellular Cl^- concentrations are high. As a
115 consequence, the activation of GABA_A or glycine receptors at inhibitory

116 synapses causes Cl^- ions to flow out of cells, thereby inducing the membrane
117 depolarization of postsynaptic neurons to exert excitatory effects rather than
118 inhibitory effects [8]. In the post-developmental state, KCC2 levels are highly
119 up-regulated to maintain a low intracellular Cl^- concentration; therefore, the
120 activation of GABA_A or glycine receptors causes Cl^- ions to flow into cells and
121 exert inhibitory effects on postsynaptic neurons [8][9][10]. However, under
122 pathological conditions, such as neuropathic pain and epilepsy, the
123 hyperexcitatory response during GABA_A /glycine receptor activation reportedly
124 re-emerges due to the down-regulation of KCC2 [11][12][13]. Based on these
125 findings, the down-regulation of KCC2 appears to cause functional abnormalities
126 in the micturition pathway. SCI has been shown to reduce the expression of
127 KCC2 in the rat lumbar spinal cord and cause disinhibition, resulting in spasticity
128 [14]. However, the role of KCC2 in SCI-induced DO is still unknown. Therefore,
129 the present study investigated whether the disruption of intracellular Cl^-
130 homeostasis associated with changes in KCC2 expression contributes to the
131 formation of hyper-excitatory responses, such as DO, in the spinal micturition
132 neural circuitry after SCI. We focused on SCI-induced changes in spinal
133 autonomic preganglionic neurons that control bladder function through
134 parasympathetic efferent pathways because these neurons reportedly receive
135 direct inhibitory inputs from GABAergic interneurons in the lumbosacral spinal
136 cord [15][16].

137

138 **Materials and Methods**

139 **Animals**

140 We used female C57BL/6 mice (8-9 weeks old; body weight of approximately
141 17-20 g, and 3-4 weeks old; body weight of 9-15 g) purchased from SLC
142 (Shizuoka, Japan). After 4 weeks, the former group of mice were used for

143 cystometry (n=40 total; n=10 per group) and immunohistochemistry at 12-13
144 weeks old (n=15 total; n=5 per group), while the latter was used for
145 electrophysiological experiments (n=22 total; SI mice: n=5, SCI mice: n=7, SCI
146 control: n=5 and SCI CLP290: n=5) at 7-8 weeks old. Mice were housed in
147 cages under a 12-hour light-dark cycle (lights off from 1900 to 0700) and were
148 allowed free access to drinking water and food pellets. All experiments were
149 performed in accordance with the guidelines issued by the Hamamatsu
150 University School of Medicine for the ethical use of animals for experimentation,
151 and all efforts were made to minimize the number of animals used and their
152 suffering.

153

154 Spinal cord surgery

155 Animals were randomly divided into SI and SCI subgroups. SCI mice were
156 created by complete transection of the Th8-9 spinal cord under 2% isoflurane
157 anesthesia. In the control group of spinal cord intact (SI) mice, the back muscle
158 incision was similarly made and sutured as sham surgery without any further
159 procedure. Antibiotics (150 mg/kg ampicillin) were administered 1 hour after
160 surgery and the day after surgery. Since the SCI group had postoperative urinary
161 retention, the bladder was emptied by manually compressing the abdominal wall
162 once daily for 4 weeks postoperatively until the final experiment. In the four
163 weeks after surgery, SCI mice developed a spinally-mediated new voiding reflex
164 with involuntary contractions of the bladder [3]. We randomly divided mice into
165 four different groups: sham surgery with vehicle administration (SI-vehicle),
166 sham surgery with CLP290 administration (SI-CLP290), SCI with vehicle

167 administration (SCI-vehicle), and SCI with CLP290 administration
168 (SCI-CLP290).

169

170 Drugs

171 The dose and method of drug administration were selected according to a
172 previous study [17]. CLP290, which is a potent activator of KCC2, was dissolved
173 in 123.62 mM dimethyl sulfoxide (DMSO) and 20%
174 2-hydroxypropyl- β -cyclodextrin, and the final dose was set to 100 mg/kg for oral
175 administration. CLP290 was administered in a single dose during each
176 experiment and the vehicle was used for control conditions.

177

178 Cystometry

179 Using SI and 4-week SCI mice (8-9 weeks old before surgery), cystometry was
180 performed under awake conditions. After anesthesia with 2% isoflurane, a
181 midline incision in the lower abdomen exposed the bladder. An SP-45 tube
182 (Natsume Seisakusho), the end of which was flared with heat, was inserted
183 through a small incision in the bladder dome, secured to the bladder with a
184 drawstring suture, and the skin wound was then closed with sutures. Mice were
185 placed in Tube Rodent Holders (Kent Scientific Corporation), and the intravesical
186 catheter was connected to a pressure transducer and syringe pump connected
187 to the PowerLab system (AD Instruments). After recovery from anesthesia,
188 which was confirmed by avoidance behavior induced by forepaw pinches, saline
189 was continuously instilled into the bladder (0.01 ml/min). After the initiation of the
190 intravesical instillation and the achievement of a stable bladder pressure

191 waveform, vehicle or CLP290 was administered to SI and SCI mice. Cystometric
192 recordings were re-started from 1 hour after vehicle or drug administration, at
193 which time the highest blood concentration of CLP290 was reportedly achieved
194 [17]. We measured intercontraction intervals (ICI), maximum voiding bladder
195 contraction pressure (MCP), intravesical baseline pressure (IVBP), post-void
196 residual urine volume (PVR), and non-voiding contractions (NVCs) counted for 1
197 hour. As reported in previous studies, ICI is the average of intervals between two
198 consecutive peaks, and PVR was measured as the amount of urine collected
199 with micro-syringe aspiration after the last voiding contraction. NVCs were
200 defined as small-amplitude bladder contractions more than 6 cmH₂O above the
201 baseline without saline leakage during the storage phase [3]. Parameters of
202 cystometry were determined at average of wave in several times.

203

204 Immunohistochemistry

205 The immediate early gene, c-fos, one of transcription factors, was used as a
206 marker of neuronal activity indicating postsynaptic activation of
207 micturition-related spinal cord neurons under SCI conditions [18]. Previous
208 studies reported the maximal expression of c-fos in the spinal cord 2 hours after
209 the intravesical infusion of saline [19]; therefore, tissues were harvested at 2
210 hours after intravesical saline infusion with vehicle or CLP290 administration. To
211 prepare fixed spinal tissues, mice were anesthetized with sodium pentobarbital
212 (50 mg/kg) and transcardially perfused with phosphate-buffered saline (PBS),
213 followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer. The
214 removed L6-S1 spinal cord was placed in 4% PFA for 1 day, followed by 30%

215 sucrose in PBS. The spinal cord was then cut into 40- μ m-thick coronal sections
216 using a cryostat. We thereafter performed triple staining for c-fos, choline
217 acetyltransferase (ChAT), and KCC2. Sections were rinsed before and between
218 incubations with 0.1% Tween 20 (Sigma-Aldrich) in PBS (PBS-T). The sections
219 were incubated at room temperature for 1 hour in blocking solution (10% normal
220 212 donkey serum in PBS-T) and then at 4°C for 24 hours with primary
221 antibodies
222 diluted in PBS-T. The following primary antibodies were used: mouse anti-c-fos
223 (1:1000; Abcam), goat anti-ChAT (1:100; Sigma-Aldrich), and rabbit anti-KCC2
224 (1:300; Abcam). The following secondary antibodies were used: Alexa Fluor
225 488-conjugated donkey anti-mouse (1:1000; Abcam), Alexa Fluor 594-
226 conjugated donkey anti-goat (1:1000; Molecular Probes), and Alexa Fluor 647-
227 conjugated donkey anti-rabbit (1:1000; Molecular Probes). Slides were mounted
228 and coverslipped sections were imaged using a confocal laser microscope (TCS
229 SP9, Leica).

230

231 *Quantification*

232 In quantitative evaluations, we included five spinal cord sections from each
233 mouse, in which c-fos IHC was positive. We only selected sections with
234 ChAT-positive cells in the SPN region of the L6-S1 spinal cord because
235 preganglionic parasympathetic cholinergic neurons in the SPN region, which
236 innervate pelvic visceral organs, including the bladder, were mostly limited to the
237 L6 caudal to S1 spinal cord levels [20]. The sections selected for quantification
238 were separated by at least 80 μ m to avoid duplicate counting. C-fos-positive

239 cells were counted in four spinal cord regions: the lateral dorsal horn (LDH),
240 medial dorsal horn (MDH), SPN, and dorsal commissure (DCM), as previously
241 reported [18]. We obtained z-stacks from every layer or region of interest
242 covering the whole thickness of the section. The number and fluorescence
243 intensity of c-fos-positive cells were measured using ImageJ software (NIH). The
244 fluorescence intensity of KCC2 was quantified as the mean value of the area
245 surrounding the cell membrane of SPN neurons using ImageJ software. We
246 subsequently measured the background intensity in each section, which was
247 defined as 100%. The fluorescence intensity of KCC2 was then divided by the
248 background intensity to calculate normalized intensity [21].

249

250 Spinal cord slice preparation

251 Acute spinal cord slices (thickness of 300 μm) were prepared from SI and
252 SCI mice (3-4 weeks old before surgery). In this experiment, we used mice at
253 younger age than those in other experiments because it was difficult to make
254 acute slice sections from matured adult mice. Slices were cut with a vibratome
255 (7000smz-2, Campden Instruments) using ice-cold cutting solution containing
256 the following (in mM): 115 N-methyl-D-glucamine-Cl, 2.5 KCl, 1.2 NaHPO₄, 0.5
257 CaCl₂, 10 MgSO₄, 25 NaHCO₃, and 25 glucose (295-305 mOsm). Slices were
258 then incubated for 10 min in the same cutting solution before being rinsed (4 \times)
259 with standard ACSF containing the following (in mM): 124 NaCl, 3 KCl, 1.2
260 NaH₂PO₄, 2 CaCl₂, 2 MgSO₄, 26 NaHCO₃, and 10 dextrose (295-305 mOsm),
261 and were then stored under continuously oxygenated conditions at room
262 temperature for approximately 1 hour.

263

264 Electrophysiological extracellular recordings and electrical stimulation

265 Spinal cord slices were transferred to a recording chamber and perfused (2
266 ml/min) with oxygenated (95% O₂/5% CO₂) recording ACSF solution containing
267 (in mM): 124 NaCl, 5 KCl, 2.7 CaCl₂, 1.3 MgSO₄, 1.25 NaH₂PO₄, 26 NaHCO₃,
268 and 10 glucose, at 30°C. Extracellular neuronal activity was recorded via a glass
269 microelectrode filled with ACSF under a microscope (BX61WI, Olympus)
270 equipped with an EMCCD camera (iXon DV887, Andor). Neuronal activity via
271 the electrodes was fed into a patch clamp amplifier (Multiclamp700B, Molecular
272 Devices). The output of the amplifier was digitized using an A/D converter
273 (Digidata 1440, Molecular Devices) with a sampling rate of 10 kHz and recorded
274 on a hard disk using data acquisition and analysis software (pCLAMP 10,
275 Molecular Devices). The firing rate of recorded neurons (spikes/s, Hz) was
276 calculated in 1-sec intervals. The dorsal root and/or LDH were stimulated once
277 every 30 s (duration of 10 ms) using a bipolar electrode to elicit the neuronal
278 firing of neurons in the SPN region. The results obtained for each group of
279 animals were normalized by the mean firing frequency during the initial 10
280 minutes after electrical stimulation. CLP290 was dissolved in 100% DMSO and
281 diluted 1000 times by ACSF to the final concentration (100 μM) just before use.
282 CLP290 was administered into the recording chamber from 20 minutes after the
283 initiation of the electrical stimulation.

284

285 Statistical analysis

286 Statistical analyses and figure generation were performed with GraphPad

287 prism 8 and Igor Pro 9 (Wavemetrics), and $P < 0.05$ was considered to be
288 significant. All data are reported as the mean \pm SEM. All comparisons among the
289 treatments were made using a paired t-test, one-way ANOVA and Tukey's post
290 hoc analysis, the Mann-Whitney U test, and Wilcoxon rank-sum test.

291

292 **Results**

293 **Changes in cystometrograms**

294 To examine whether NVCs were affected by the activation of KCC2,
295 CLP290 was orally administered to SCI mice, and NVCs were compared before
296 and after administration (Figure 1A, B). The number of NVCs was significantly
297 lower after CLP290 administration compared to pre-administration of CLP290
298 (Figure 1C). The amplitude of NVCs was also significantly after CLP290
299 administration than that before administration (Figure 1D). Next, we compared
300 the results of cystometric analyses among 4 groups of SCI and SI mice
301 administered with vehicle or CLP290 (Figure 2). A larger number of NVCs with
302 higher amplitudes were observed in the SCI-vehicle group than in the SI-vehicle
303 group (Figure 2C, H, I). However, the number and amplitude of NVCs were
304 significantly lower in the SCI-CLP290 group than in the SCI-vehicle group
305 (Figure 2D, H, I). PVR was higher in the SCI-vehicle group than in the SI-vehicle,
306 but was not significantly altered by CLP290 (Figure 2J). No significant
307 differences were observed in ICI or MCP among the 4 groups (Figure 2E, F).
308 The administration of CLP290 to SI mice did not alter any parameters. These
309 results suggest that DO, evident as a large number of NVCs with a high
310 amplitude in SCI mice, was decreased by KCC2 activation. Since no significant

311 differences were observed between the SI-vehicle and SI-CLP290 groups, the
312 following histological and electrophysiological experiments used only the
313 SI-vehicle group for comparisons with SCI-vehicle and SCI-CLP290 groups.

314

315 **Changes in *c-fos* expression**

316 To confirm whether the activation of spinal cord neurons involved in DO
317 was reduced by the administration of CLP290, *c-fos* expression in the L6-S1
318 spinal cord following intravesical saline instillation for 2 hours was compared
319 among SI-vehicle, SCI-vehicle, and SCI-CLP290 groups. We divided each spinal
320 cord section into four regions: LDH, MDH, SPN, and DCM, and counted the
321 number of *c-fos*-positive cells in each region (Figure 3A). The number of
322 *c-fos*-positive neurons was higher in all 4 regions in the SCI-vehicle group than
323 in the SI-vehicle group. In comparisons between the SI-vehicle and SCI-CLP290
324 groups, the number of *c-fos*-positive cells was still increased significantly in the
325 MDH and DCN regions, but not in the LDH or SPN region in the SCI-CLP290
326 group, indicating that the CLP290 treatment reduced bladder distention-induced
327 neuronal activity in the latter two regions in SCI mice. We also confirmed that the
328 number of *c-fos*-positive cells showed the greatest difference between the
329 SCI-vehicle and SI-vehicle groups in the SPN region (Figure 3B-E), which
330 contains parasympathetic preganglionic neurons innervating the lower urinary
331 tract [19].

332 Since the greatest changes in neural activity after SCI were observed in
333 the SPN region, we evaluated *c-fos* expression in ChAT-positive preganglionic
334 parasympathetic neurons in the SPN region of the L6-S1 spinal cord. KCC2

335 co-expression in ChAT- and c-fos-positive neurons in the SPN region was also
336 examined to establish whether KCC2 contributed to the therapeutic effects of the
337 CLP290 treatment on DO in SCI mice. KCC2 immunoreactivity was observed in
338 ChAT-positive parasympathetic preganglionic cells in the SPN region in all
339 groups (Figure 3F-H). The number of ChAT-positive cells was similar among the
340 3 groups; however, the co-expression of c-fos and ChAT, which was higher in the
341 SCI-vehicle group than in the SI-vehicle group, was significantly lower in the
342 SCI-CLP290 group than in the SCI-vehicle group (Figure 3I, J). We then
343 compared the normalized fluorescence intensity of KCC2 in cells co-expressing
344 ChAT and c-fos. The normalized fluorescence intensity of KCC2 was lower in the
345 SCI-vehicle group than in the SI-vehicle group, but was significantly higher in the
346 SCI-CLP290 group than in the SCI-vehicle group (Figure 3K), indicating that the
347 CLP290 treatment restored the down-regulation of KCC2 induced by SCI in
348 preganglionic parasympathetic neurons located at the SPN region.

349

350 **Functional effects of KCC2 on neuronal activity in the SPN region**

351 To establish whether the activation of KCC2 by CLP290 directly altered
352 neural activity in the SPN region, neuronal firing properties were evaluated
353 extracellularly in SPN neurons using L6-S1 spinal cord slice preparations (Figure
354 4A). The locations of recorded neurons were optically confirmed after each
355 recording, and neurons outside the SPN region were excluded from the results
356 (Figure 4B). Little is known about neural activity in the SPN region of SI mice
357 although a recent study demonstrated that capsaicin activation of primary
358 afferents induced excitatory currents in mouse lumbosacral preganglionic

359 neurons identified by retrograde axonal transport using patch clamp recordings
360 [22]. Therefore, we compared neural activity recorded from the SPN region of SI
361 and SCI mice. Recordings were started without an electrical stimulation for the
362 first 20 minutes, and a stimulation was then applied to the dorsal root or horn of
363 the spinal cord section in order to activate afferent inputs to SPN neurons
364 (Figure 4C). In the absence of the electrical stimulation, the baseline firing
365 frequency recorded from SCI mice was slightly higher than that from SI mice
366 (Figure 4C, D). However, following the electrical stimulation in SCI mice, the
367 firing frequency at 30 to 40 minutes was significantly higher than that during the
368 initial 0 to 10 minutes without the stimulation. In contrast, SI mice did not show
369 any changes in the firing frequency over time (Figure 4D). These results suggest
370 that SPN neurons in SCI mice increased their excitability in response to afferent
371 inputs conveyed through dorsal roots. To clarify whether this increased
372 excitability was due to the altered expression of KCC2, we investigated the
373 effects of CLP290, a potent KCC2 activator, on responses to the electrical
374 stimulation in SCI mice. CLP290 was applied to a recording chamber 20 minutes
375 after the electrical stimulation was started. The normalized firing frequency of
376 SPN neurons at 40 to 60 minutes was significantly lower in the SCI-CLP290
377 group than in the SCI control group (Figure 4E, F). These results suggest that
378 the increased excitability of SPN neurons was at least partly due to the
379 decreased activity of KCC2.

380

381 **Discussion**

382 Our results showed that SCI-induced DO is associated with

383 downregulation of KCC2 in ChAT-positive preganglionic parasympathetic
384 neurons in the L6-S1 spinal cord, and that activation of KCC2 transporters by
385 CLP290 can reduce DO, increase KCC2 expression in preganglionic
386 parasympathetic neurons and decrease neuronal firing of SPN neurons in SCI
387 mice. To the best of our knowledge, this is the first study to show that the
388 down-regulation of KCC2 contributed to the hyperexcitability of the efferent
389 pathway innervating the bladder that induces DO after SCI.

390 To elucidate the post-SCI neural mechanisms inducing LUTD, such as DO,
391 previous studies mostly focused on changes in bladder afferent pathways after
392 SCI. Afferent pathways innervating the bladder consist of A δ - and C-fiber
393 afferents, and following SCI, C-fiber bladder afferent pathways become
394 hyperexcitable to reorganize the spinally-mediated micturition reflex, leading to
395 DO [3][4][23]. Furthermore, previous studies showed that C-fiber desensitization
396 by the administration of capsaicin to SCI rats and mice significantly reduced the
397 number of NVCs without affecting the bladder capacity or reflex voiding [3][4][23],
398 suggesting that capsaicin-sensitive C-fiber afferent pathways play a major role in
399 the initiation of DO, whereas voiding detrusor contractions are still triggered by
400 A δ -fiber afferents in SCI rodents. In the present study, the administration of
401 CLP290 attenuated DO, as evidenced by a reduction in NVCs during the storage
402 phase without affecting the voiding reflex because MCP, ICI, and PVR in the
403 SCI-CLP290 group were similar to those in the SI-vehicle group. Therefore, the
404 down-regulation of KCC2 appears to be involved in the enhancement of spinal
405 micturition reflexes triggered by C-fiber afferents connecting to preganglionic
406 parasympathetic efferent neurons, which induces DO without affecting voiding
407 parameters. Furthermore, SCI is known to induce urethral dysfunction, called
408 detrusor sphincter dyssynergia (DSD), during the voiding phase, leading to high
409 PVR, as also shown in this study [4]. ICI and PVR of the SCI-CLP290 group

410 tended to decrease compared to the SCI-vehicle group although no significant
411 difference was observed. In this study, we did not investigate SCI-induced
412 voiding dysfunctions, such as reduced voiding efficiency or DSD, which may be
413 evaluated by external urethral sphincter electromyography. Therefore, it is
414 necessary to conduct further experiments regarding this point in the future.

415 In the present study, we showed that the expression of KCC2 within the
416 SPN region of the L6-S1 spinal cord was decreased after SCI and then restored
417 by the administration of CLP290. KCC2 messenger RNA is abundantly
418 expressed in most neurons throughout the nervous system, and KCC2 is known
419 to pump out Cl⁻ ions in response to the influx of Cl⁻ via GABA_A or glycine receptor
420 activation [24]. Therefore, the down-regulation of KCC2 results in high
421 intracellular Cl⁻ concentrations, which depolarize the Cl⁻ equilibrium potential,
422 leading to a decrease in inhibitory responses during GABA_A/glycine inhibitory
423 receptor activation, similar to that in the developmental phase [9][10]. Previous
424 studies reported that GAD and glycine levels were decreased in the L6-S1 spinal
425 cord after SCI and also that GABA receptor activation, GAD gene delivery, and
426 glycine administration attenuated DO in SCI rats [5][6][25]. The reduction of
427 inhibitory interneurons weakens the inhibitory response, but the present study
428 indicates that the down-regulation of KCC2 in ChAT-positive neurons, which
429 reduces inhibitory responses at the postsynaptic ChAT-positive neurons, play a
430 significant role in the enhanced C-fiber-to-parasympathetic spinal reflex pathway
431 responsible for DO after SCI [3][4]. Moreover, the presynaptic terminals of
432 bladder afferent nerve boutons have been shown to express GABA and/or
433 glycine immunopositivity and reach the dorsal horn and SPN in the L6-S1 spinal
434 cord [26]. Furthermore, using slice patch-clamp techniques, the electrical
435 stimulation of GABAergic interneurons was found to induce direct inhibitory
436 responses on preganglionic parasympathetic neurons in L6-S1 spinal cord slices

437 [15]. These data indicate that bladder afferent nerves and spinal interneurons
438 send GABAergic and/or glycinergic inputs to SPN neurons to induce inhibitory
439 neurotransmission in the normal condition. Therefore, the present study focused
440 on the plasticity of spinal efferent pathways, particularly KCC2-mediated
441 functional changes in preganglionic parasympathetic neurons in the SPN and
442 demonstrated that the down-regulation of KCC2 in cholinergic SPN neurons
443 contributed to the efferent side of neuroplasticity involved in DO after SCI.

444 Spinal cord neural circuits are reorganized following SCI, and the
445 appearance of the C-fiber-dependent, spinally-mediated micturition reflex
446 pathway causes involuntary micturition and DO [3][4]. We compared the results
447 obtained by immunostaining (c-fos and ChAT staining) and extracellular
448 recordings in the SPN region between SI and SCI mice. After SCI, a previous
449 study reported that the total number of ChAT-positive cells in the SPN region
450 was the same as that in SI mice and also that the co-expression of c-fos/ChAT
451 was increased in SCI mice [19]. Im et al. [27] showed that $82.4 \pm 10.3\%$ of
452 ChAT-positive cells were positive for c-fos in the SPN region of SCI mice. These
453 findings suggest the involvement of the excessive activation of preganglionic
454 parasympathetic cholinergic neurons in bladder efferent hyperexcitability during
455 spinal cord reorganization, which contributes to the emergence of DO after SCI.
456 However, neuronal activity in the SPN region between SI and SCI adult mice has
457 not yet been examined using electrophysiological techniques. In the present
458 study, the firing of SPN neurons during the electrical stimulation of the dorsal
459 root or spinal dorsal horn was more frequent in SCI mice than in SI mice, and the
460 bath application of CLP290 significantly reduced the firing rate from that in
461 untreated SPN cells of SCI mice.

462 The present results indicated that the single dose administration of
463 CLP290 was sufficient to modulate the activity of KCC2, which led to positive

464 results in immunostaining and electrophysiology experiments. CLP290 is
465 considered to be a promising pharmaceutical agent as a KCC2 activator
466 because it has been shown to induce phosphorylation of Ser940 in KCC2
467 [28][29][30]. The phosphorylation of Ser940 is known to cause membrane
468 relocation of KCC2, suggesting that CLP290 upregulates KCC2 function [31].
469 Furthermore, in the present study, the single dose administration of CLP290
470 increased the protein expression of KCC2 in ChAT-positive preganglionic
471 parasympathetic neurons, possibly due to the cell membrane insertion of
472 transporter proteins after the activation of KCC2. Further studies are needed to
473 elucidate the mechanisms underlying the effects of CLP290 on the activation of
474 KCC2 in bladder efferent pathways.

475 There are some limitations that need to be addressed, which were
476 mainly technical issues. We measured the activity of putative preganglionic
477 parasympathetic neurons in SPN region using extracellular recordings without
478 verifying whether they were cholinergic neurons or if CLP290-induced changes
479 in neuronal activity were dependent on GABAergic or glycinergic inputs.
480 Furthermore, the mechanisms inducing the down-regulation of KCC2 in SPN
481 neurons after SCI remain unknown even though previous studies demonstrated
482 that brain-derived neurotrophic factor (BDNF) may contribute to the
483 down-regulation of KCC2 in the spinal cord of SCI rats with spasticity [14] and
484 also that spinal BDNF protein expression was increased in the L6-S1 spinal cord
485 of SCI mice with LUTD [32]. Therefore, future studies are warranted to
486 investigate KCC2 mechanisms, such as interactions with BDNF, which may be
487 involved in SCI-induced LUTD, including voiding dysfunction.

488 In conclusion, this is the first study to show that the down-regulation of
489 KCC2 was involved in bladder efferent hyperexcitability, which induces DO in
490 SCI mice, and also that the activation of KCC2 effectively suppressed the

491 excessive activity of parasympathetic preganglionic neurons in the L6-S1 spinal
492 cord and attenuated DO after SCI. Therefore, the administration of KCC2
493 activators, such as CLP290, have potential as new therapeutic agents for the
494 treatment of SCI-induced DO by targeting bladder efferent pathways.

495

496 **Compliance with ethical standards**

497 **Conflicts of interest** All authors have declared no conflicts of interest.

498

499 **Funding**

500 This work was supported by a Grant-in-Aid for Scientific Research (B) (no.
501 17H04025) from the Japan Society for the Promotion of Science; Research
502 Grants from The Smoking Research Foundation; Research Grants (no. 2138)
503 from The Salt Science Research Foundation; a Grant-in-Aid for Scientific
504 Research on Innovative Areas (no. 21H05687) from the Ministry of Education,
505 Culture, Sports, and Science and Technology, Japan; a Grant-in-Aid for
506 Scientific Research (B) (no. 21H02661) from the Japan Society for the
507 Promotion of Science, to A.F.; a HUSM Grant-in-Aid to K.W.; a Grant-in-Aid for
508 Scientific Research (C) (no. 19K07284) from the Japan Society for the
509 Promotion of Science; Research Grants (JERF TENKAN 20002) from the Japan
510 Epilepsy Research Foundation to M.I.; a GSK Japan Research Grant 2020 to
511 T.S.; and a Grant-in-Aid for Scientific Research (C) (no. 19K09669) from the
512 Japan Society for the Promotion of Science to A.O.

513

514 **Acknowledgments**

515 We are grateful to Prof. William C. de Groat (Department of Pharmacology and
516 Chemical Biology, University of Pittsburgh School of Medicine) and Prof.
517 Christopher S. Leonard (Department of Physiology, New York Medical College)

518 for helpful discussion and comments on the manuscript. We also thank Dr.
519 Makoto Goda (Advanced Research Facilities and Services of Hamamatsu
520 University School of Medicine) for assistance with imaging and image analyses.
521
522
523

524 **References**

- 525 1. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M,
526 Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O. Symptom assessment
527 tool for overactive bladder syndrome--overactive bladder symptom score.
528 *Urology* 68:318-323, 2006. doi:10.1016/j.urology.2006.02.042.
- 529 2. Gillespie JI. A developing view of the origins of urgency: the importance of
530 animal models. *BJU Int* 1: 22-28, 2005. doi:
531 10.1111/j.1464-410X.2005.05652.x.
- 532 3. de Groat WC, Griffiths D, Yoshimura N. Neural control of the lower urinary
533 tract. *Compr Physiol. Compr Physiol* 5: 327-396, 2015. doi:
534 10.1002/cphy.c130056.
- 535 4. Wada N, Karnup S, Kadekawa K, Shimizu N, Kwon J, Shimizu T, Gotoh D,
536 Kakizaki H, de Groat WC, Yoshimura N. Current knowledges and novel
537 frontiers in lower urinary tract dysfunction after spinal cord injury- Basic
538 research perspectives. *Urological Science* 33: 101-113, 2022. doi:
539 10.4103/uros.uros_31_22.
- 540 5. Miyazato M, Sasatomi K, Hiragata S, Sugaya K, Chancellor MB, de Groat
541 WC, Yoshimura N. GABA receptor activation in the lumbosacral spinal cord
542 decreases detrusor overactivity in spinal cord injured rats. *J Urol* 179:
543 1178-1183, 2008. doi: 10.1016/j.juro.2007.10.030.
- 544 6. Miyazato M, Sugaya K, Nishijima S, Ashitomi K, Morozumi M, Ogawa Y.
545 Dietary glycine inhibits bladder activity in normal rats and rats with spinal
546 cord injury. *J Urol* 173:314-317, 2005. doi:
547 10.1097/01.ju.0000141579.91638.a3.

- 548 7. Toyoda H, Ohno K, Yamada J, Ikeda M, Okabe A, Sato K, Hashimoto K,
549 Fukuda A. Induction of NMDA and GABAA receptor-mediated Ca²⁺
550 oscillations with KCC2 mRNA downregulation in injured facial motoneurons.
551 J Neurophysiol 89: 1353-1362, 2003. doi: 10.1152/jn.00721.2002.
- 552 8. Yamada J, Okabe A, Toyoda H, Kilb W, Luhmann HJ, Fukuda A. Cl⁻ uptake
553 promoting depolarizing GABA actions in immature rat neocortical neurones
554 is mediated by NKCC1. J Physiol 557: 829-841, 2004. 10.1113/jphysiol.
555 2004. 062471.
- 556 9. Watanabe M, Zhang J, Mansuri MS, Duan J, Karimy JK, Delpire E, Alper SL,
557 Lifton RP, Fukuda A, Kahle KT. Developmentally regulated KCC2
558 phosphorylation is essential for dynamic GABA-mediated inhibition and
559 survival. Sci Signal 12: eaaw9315, 2019. doi: 10.1126/scisignal.aaw9315.
- 560 10. Rivera C, Voipio J, Payne JA, Ruusuvuori E, Lahtinen H, Lamsa K, Pirvola U,
561 Saarma M, Kaila K. The K⁺/Cl⁻ co-transporter KCC2 renders GABA
562 hyperpolarizing during neuronal maturation. Nature 397: 251-255, 1999. doi:
563 10.1038/16697.
- 564 11. Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sk A, De Koninck P,
565 De Koninck Y. Trans-synaptic shift in anion gradient in spinal lamina I
566 neurons as a mechanism of neuropathic pain. Nature 424: 938-942, 2003.
567 doi: 10.1038/nature01868.
- 568 12. Shimizu-Okabe C, Okabe A, Kilb W, Sato K, Luhmann HJ, Fukuda A.
569 Changes in the expression of cation-Cl⁻ cotransporters, NKCC1 and KCC2,
570 during cortical malformation induced by neonatal freeze-lesion. Neurosci
571 Res 59: 288-295, 2007. doi: 10.1016/j.neures.2007.07.010.

- 572 13. Shimizu-Okabe C, Tanaka M, Matsuda K, Mihara T, Okabe A, Sato K, Inoue
573 Y, Fujiwara T, Yagi K, Fukuda A. KCC2 was downregulated in small neurons
574 localized in epileptogenic human focal cortical dysplasia. *Epilepsy Res* 93:
575 177-184, 2011. doi: 10.1016/j.eplepsyres.2010.12.008.
- 576 14. Boulenguez P, Liabeuf S, Bos R, Bras H, Jean-Xavier C, Brocard C, Stil A,
577 Darbon P, Cattaert D, Delpire E, Marsala M, Vinay L. Down-regulation of the
578 potassium-chloride cotransporter KCC2 contributes to spasticity after spinal
579 cord injury. *Nat Med* 16: 302-307, 2010. doi: 10.1038/nm.2107.
- 580 15. Araki I. Inhibitory postsynaptic currents and the effects of GABA on visually
581 identified sacral parasympathetic preganglionic neurons in neonatal rats. *J*
582 *Neurophysiol* 72:2903-2910, 1994. doi: 10.1152/jn.1994.72.6.2903.
- 583 16. Karnup S. Spinal interneurons of the lower urinary tract circuits. *Auton*
584 *Neurosci* 235:102861, 2021. doi: 10.1016/j.autneu.2021.102861.
- 585 17. Gagnon M, Bergeron MJ, Lavertu G, Castonguay A, Tripathy S, Bonin RP,
586 Perez-Sanchez J, Boudreau D, Wang B, Dumas L, Valade I, Bachand K,
587 Jacob-Wagner M, Tardif C, Kianicka I, Isenring P, Attardo G, Coull JA, De
588 Koninck Y. Chloride extrusion enhancers as novel therapeutics for
589 neurological diseases. *Nat Med* 19: 1524-1528, 2013. doi:
590 10.1038/nm.3356.
- 591 18. Vizzard MA. Increased expression of spinal cord Fos protein induced by
592 bladder stimulation after spinal cord injury. *Am J Physiol Regul Integr Comp*
593 *Physiol* 279:295-305, 2000. doi: 10.1152/ajpregu.2000.279.1.R295.
- 594 19. Birder LA, de Groat WC. Increased c-fos expression in spinal neurons after
595 irritation of the lower urinary tract in the rat. *J Neurosci* 12: 4878-4889, 1992.

- 596 doi: 10.1523/JNEUROSCI.12-12-04878.1992.
- 597 20. Fuller-Jackson JP, Osborne PB, Keast JR. Regional Targeting of Bladder
598 and Urethra Afferents in the Lumbosacral Spinal Cord of Male and Female
599 Rats: A Multiscale Analysis. *eNeuro* 8: 0364-21, 2021. doi:
600 10.1523/ENEURO.0364-21.2021.
- 601 21. Kakizawa K, Watanabe M, Mutoh H, Okawa Y, Yamashita M, Yanagawa Y,
602 Itoi K, Suda T, Oki Y, Fukuda A. A novel GABA-mediated
603 corticotropin-releasing hormone secretory mechanism in the median
604 eminence. *Sci Adv* 2: e1501723, 2016. doi: 10.1126/sciadv.1501723.
- 605 22. Kawatani M, de Groat WC, Itoi K, Uchida K, Sakimura K, Yamanaka A,
606 Yamashita T, Kawatani M. Downstream projection of Barrington's nucleus to
607 the spinal cord in mice. *J Neurophysiol* 126:1959-1977, 2021. doi:
608 10.1152/jn.00026.2021.
- 609 23. Kadekawa K, Majima T, Shimizu T, Wada N, de Groat WC, Kanai AJ, Goto M,
610 Yoshiyama M, Sugaya K, Yoshimura N. The role of capsaicin-sensitive
611 C-fiber afferent pathways in the control of micturition in spinal-intact and
612 spinal cord-injured mice. *Am J Physiol Renal Physiol* 313: 796-804, 2017.
613 doi: 10.1152/ajprenal.00097.2017.
- 614 24. Kanaka C, Ohno K, Okabe A, Kuriyama K, Itoh T, Fukuda A, Sato K. The
615 differential expression patterns of messenger RNAs encoding K-Cl
616 cotransporters (KCC1,2) and Na-K-2Cl cotransporter (NKCC1) in the rat
617 nervous system. *Neuroscience* 10: 933-946, 2001. doi:
618 10.1016/s0306-4522(01)00149-x.
- 619 25. Miyazato M, Sugaya K, Goins WF, Wolfe D, Goss JR, Chancellor MB, de

- 620 Groat WC, Glorioso JC, Yoshimura N. Herpes simplex virus vector-mediated
621 gene delivery of glutamic acid decarboxylase reduces detrusor overactivity
622 in spinal cord-injured rats. *Gene Ther* 16: 660-668, 2009. doi:
623 10.1038/gt.2009.5.
- 624 26. Park SK, Devi AP, Bae JY, Cho YS, Ko HG, Kim DY, Bae YC. Synaptic
625 connectivity of urinary bladder afferents in the rat superficial dorsal horn and
626 spinal parasympathetic nucleus. *J Comp Neurol* 15: 3002-3013, 2019. doi:
627 10.1002/cne.24725.
- 628 27. Im YJ, Hong CH, Jin MH, Lee BH, Han SW. c-fos expression in
629 bladder-specific spinal neurons after spinal cord injury using pseudorabies
630 virus. *Yonsei Med J* 49: 479-485, 2008. doi: 10.3349/ymj.2008.49.3.479.
- 631 28. Ferrini F, Lorenzo LE, Godin AG, Quang ML, De Koninck Y. Enhancing
632 KCC2 function counteracts morphine-induced hyperalgesia. *Sci Rep* 7: 3870,
633 2017. doi: 10.1038/s41598-017-04209-3.
- 634 29. Lizhnyak PN, Muldoon PP, Pilaka PP, Povlishock JT, Ottens AK. Traumatic
635 Brain Injury Temporal Proteome Guides KCC2-Targeted Therapy. *J*
636 *Neurotrauma* 36: 3092-3102, 2019. doi: 10.1089/neu.2019.6415.
- 637 30. Sullivan BJ, Kipnis PA, Carter BM, Shao LR, Kadam SD. Targeting
638 ischemia-induced KCC2 hypofunction rescues refractory neonatal seizures
639 and mitigates epileptogenesis in a mouse model. *Sci Signal*. 14: eabg2648,
640 2021. doi: 10.1126/scisignal.abg2648.
- 641 31. Lee HH, Walker JA, Williams JR, Goodier RJ, Payne JA, Moss SJ. Direct
642 protein kinase C-dependent phosphorylation regulates the cell surface
643 stability and activity of the potassium chloride cotransporter KCC2. *J Biol*

644 Chem. 282:29777-84, 2007. doi: 10.1074/jbc.M705053200.
645 32. Wada N, Shimizu T, Shimizu N, Kurobe M, de Groat WC, Tyagi P, Kakizaki H,
646 Yoshimura N. Therapeutic effects of inhibition of brain-derived neurotrophic
647 factor on voiding dysfunction in mice with spinal cord injury. Am J Physiol
648 Renal Physiol 1305-1310, 2019. doi: 10.1152/ajprenal.00239.2019.
649

650 Figure legends

651

652 **Figure1. Changes in cystometrograms before and after oral administration**
653 **of CLP290 to SCI mice.**

654 (A-B), Representative cystometrograms (CMG) before and after the
655 administration of CLP290 to SCI mice (n=10). Black arrows indicate voiding
656 contractions. Asterisks indicate NVCs. (A) Before administration of CLP290 to
657 SCI mice. (B) After administration of CLP290 to SCI mice. (C) The number of
658 NVCs was significantly lower in the after administration of CLP290 than in the
659 before administration of CLP290. (D) The amplitude of NVCs was also
660 significantly lower in the after administration of CLP290 than in the before
661 administration of CLP290. SCI; spinal cord injury, NVC; non-voiding contraction,
662 ### P <0.001, paired t-test.

663

664 **Figure2. Comparison of cystometrograms among 4 experimental groups**
665 **with or without oral administration of CLP290.**

666 (A-D), Representative cystometrograms (CMG) after oral administration of
667 vehicle or CLP290 to SI and SCI mice. Black arrows indicate voiding
668 contractions. Asterisks indicate NVCs. (A) Vehicle administration to SI mice. (B)
669 CLP290 administration to SI mice. The administration of CLP290 to SI mice did
670 not alter any parameter. (C) Vehicle administration to SCI mice. (D) CLP290
671 administration to SCI mice. The number and amplitude of NVCs decreased.
672 (E-J), Results of CMG parameters among 4 groups (n=10 in each). (E, F) There
673 was no significant difference in ICI or MCP among the 4 groups. (G) IVBP was
674 higher in the SCI-vehicle group than in the SI-vehicle group. (H) The number of
675 NVCs was significantly lower in the SCI-CLP290 group than in the SCI-vehicle
676 group. (I) The amplitude of NVCs was also significantly lower in the SCI-CLP290

677 group than in the SCI-vehicle group. (J) PVR was significantly increased in the
678 SCI-vehicle and SCI-CLP290 groups.

679 SI; spinal cord intact, SCI; spinal cord injury, NVC; non-voiding contraction, ICI;
680 intercontraction interval, MCP; maximum voiding bladder contraction pressure,
681 IVBP; intravesical baseline pressure, NVC; non-voiding contraction, PVR;
682 post-void residual urine volume. # $P < 0.05$, ### $P < 0.001$, One-way ANOVA and
683 Tukey's post hoc analysis.

684

685 **Figure3. Changes of c-fos, ChAT and KCC2 expression in the spinal cord**
686 **among 4 experimental groups with or without oral administration of**
687 **CLP290.**

688 Immunohistochemistry of the L6/S1 segment. (A) Illustration of each segment of
689 the spinal cord. The scale bar is 200 μm . (B-E) Comparison of c-fos-positive cell
690 counts in the LDH, SPN, MDH, and DCN regions. The number of c-fos-positive
691 cells was significantly increased in the SCI-vehicle group, particularly in the SPN
692 region. (F-H) Comparison of c-fos-, ChAT-, and KCC2-positive cells in the SPN
693 region. KCC2 expression was confirmed on the cell membrane in all three
694 groups. Red circles show ChAT-positive cells, and yellow circles show c-fos- and
695 ChAT-positive cells. Scale bars are 50 μm . (I) Comparison of the number of
696 ChAT-positive cells in the SPN region. There was no significant difference in the
697 number of ChAT-positive cells among the three groups. (J) Percentage of
698 co-expression of c-fos- and ChAT-positive cells. The co-expression of c-fos- and
699 ChAT-positive cells was significantly higher in the SCI-vehicle group than in the
700 SI-vehicle group, but was significantly lower in the SCI-CLP290 group than in
701 the SCI-vehicle group. (K) Normalized intensity of KCC2. KCC2 was lower in the
702 SCI-vehicle group than in the SI vehicle group. KCC2 was higher in the
703 SCI-CLP290 group than in the SCI-vehicle group.

704 LDH; lateral dorsal horn, SPN; sacral parasympathetic nucleus, MDH; medial
705 dorsal horn, DCN; dorsal commissural nucleus, KCC2; K^+ - Cl^- co-transporter 2;
706 ChAT; choline acetyltransferase. # $p < 0.05$, ### $p < 0.001$ One-way ANOVA and
707 Tukey's post hoc analysis.

708

709 **Figure4. Functional effects of KCC2 activation on neuronal activity in the**
710 **SPN region.**

711 (A) Example recordings of firing transitions in the SPN region of the L6/S1 spinal
712 cord segment. An action potential in the arrow is expanded and shown on the
713 right panel. (B) The stimulation electrode was located in the dorsal horn, and the
714 recording electrode on the external side of the SPN region. The scale bar is 200
715 μ m. (C, D) In each recording, it was confirmed whether the stimulation electrode
716 was located in the SPN region. In cells in the SPN region of SCI mice, the firing
717 frequency was increased during the stimulation. At 30 to 40 minutes, the firing
718 frequency in SCI mice after the stimulation was higher than that before the
719 stimulation and was also significantly higher than that in SI mice. (E, F) At 40 to
720 60 minutes, the CLP290-administered group showed a lower normalized
721 frequency than that in the control group. The frequency of each recording was
722 normalized with an average value in the range of 0.5 to 10 minutes.

723 Data are presented as the \pm standard error of the mean (\pm SEM). * $p < 0.05$ (vs 0 to
724 10 min), # $p < 0.05$ (SI mice vs SCI mice), && $p < 0.01$ (CLP290 vs control), the
725 Mann-Whitney U test and the Wilcoxon rank-sum test.

726

Figure 1.




Figure 1. Changes in cystometrograms before and after oral administration of CLP290 to SCI mice. (A-B), Representative cystometrograms (CMG) before and after the administration of CLP290 to SCI mice (n=10). Black arrows indicate voiding contractions. Asterisks indicate NVCs. (A) Before administration of CLP290 to SCI mice. (B) After administration of CLP290 to SCI mice. (C) The number of NVCs was significantly lower in the after administration of CLP290 than in the before administration of CLP290. (D) The amplitude of NVCs was also significantly lower in the after administration of CLP290 than in the before administration of CLP290. SCI; spinal cord injury. NVC; non-voiding contraction. ### P < 0.001, paired t-test.

Figure2.




Figure2. Comparison of cystometrograms among 4 experimental groups with or without oral administration of CLP290.

(A-D), Representative cystometrograms (CMG) after oral administration of vehicle or CLP290 to SI and SCI mice. Black arrows indicate voiding contractions. Asterisks indicate NVCs. (A) Vehicle administration to SI mice. (B) CLP290 administration to SI mice. The administration of CLP290 to SI mice did not alter any parameter. (C) Vehicle administration to SCI mice. (D) CLP290 administration to SCI mice. The number and amplitude of NVCs decreased. (E-J), Results of CMG parameters among 4 groups (n=10 in each). (E, F) There was no significant difference in ICI or MCP among the 4 groups. (G) IVBP was higher in the SCI-vehicle group than in the SI-vehicle group. (H) The number of NVCs was significantly lower in the SCI-CLP290 group than in the SCI-vehicle group. (I) The amplitude of NVCs was also significantly lower in the SCI-CLP290 group than in the SCI-vehicle group. (J) PVR was significantly increased in the SCI-vehicle and SCI-CLP290 groups.

SI; spinal cord intact, SCI; spinal cord injury, NVC; non-voiding contraction, ICI; intercontraction interval, MCP; maximum voiding contraction pressure, IVBP; intravesical baseline pressure, NVC; non-voiding contraction, PVR; post-void residual urine volume. # P <0.05, ### P <0.001, One-way ANOVA and Tukey's post hoc analysis.

Figure 3.




Figure 3. Changes of c-fos, ChAT and KCC2 expression in the spinal cord among 4 experimental groups with or without oral administration of CLP290. Immunohistochemistry of the L6/S1 segment. (A) Illustration of each segment of the spinal cord. The scale bar is 200 μm . (B-E) Comparison of c-fos-positive cell counts in the LDH, SPN, MDH, and DCN regions. The number of c-fos-positive cells was significantly increased in the SCI-vehicle group, particularly in the SPN region. (F-H) Comparison of c-fos-, ChAT-, and KCC2-positive cells in the SPN region. KCC2 expression was confirmed on the cell membrane in all three groups. Red circles show ChAT-positive cells, and yellow circles show c-fos- and ChAT-positive cells. Scale bars are 50 μm . (I) Comparison of the number of ChAT-positive cells in the SPN region. There was no significant difference in the number of ChAT-positive cells among the three groups. (J) Percentage of co-expression of c-fos- and ChAT-positive cells. The co-expression of c-fos- and ChAT-positive cells was significantly higher in the SCI-vehicle group than in the SI-vehicle group, but was significantly lower in the SCI-CLP290 group than in the SCI-vehicle group. (K) Normalized intensity of KCC2. KCC2 was lower in the SCI-vehicle group than in the SI vehicle group. KCC2 was higher in the SCI-CLP290 group than in the SCI-vehicle group. LDH; lateral dorsal horn, SPN; sacral parasympathetic nucleus, MDH; medial dorsal horn, DCN; dorsal commissural nucleus, KCC2; K⁺-Cl⁻ co-transporter 2; ChAT; choline acetyltransferase. # p<0.05, ### p<0.001 One-way ANOVA and Tukey's post hoc analysis.

Figure 4.




Figure 4. Functional effects of KCC2 activation on neuronal activity in the SPN region.


(A) Example recordings of firing transitions in the SPN region of the L6/S1 spinal cord segment. An action potential in the arrow is expanded and shown on the right panel. (B) The stimulation electrode was located in the dorsal horn, and the recording electrode on the external side of the SPN region. The scale bar is 200 μ m. (C, D) In each recording, it was confirmed whether the stimulation electrode was located in the SPN region. In cells in the SPN region of SCI mice, the firing frequency was increased during the stimulation. At 30 to 40 minutes, the firing frequency in SCI mice after the stimulation was higher than that before the stimulation and was also significantly higher than that in SI mice. (E, F) At 40 to 60 minutes, the CLP290-administered group showed a lower normalized frequency than that in the control group. The frequency of each recording was normalized with an average value in the range of 0.5 to 10 minutes. Data are presented as the \pm standard error of the mean (\pm SEM). * $p < 0.05$ (vs 0 to 10 min), # $p < 0.05$ (SI mice vs SCI mice), && $p < 0.01$ (CLP290 vs control), the Mann-Whitney U test and the Wilcoxon rank-sum test.

Therapeutic effects of KCC2 activation on detrusor overactivity in mice with spinal cord injury


METHODS

SCI was produced by the Th8-9 spinal cord transection in female C57BL/6 mice. At 4 weeks after SCI, CLP290, a KCC2 activator was administered, and cystometry was performed. Thereafter, neuronal activity with c-fos staining and KCC2 expression in the cholinergic preganglionic parasympathetic neurons in the SPN were examined using immunohistochemistry. In a separate group of animals, firing properties of neurons in the SPN region were evaluated by extracellular recordings in spinal cord slice preparations.


OUTCOME



DO evident as non-voiding contractions (NVC) was significantly reduced by CLP290 treatment in SCI mice.



CLP290 administration suppressed the high frequency firing activity of SPN neurons in SCI mice.



The number of c-fos-positive cells and co-expression of c-fos in choline acetyltransferase (ChAT)-positive cells were decreased in the SPN region of SCI-CLP290 group vs. SCI-vehicle group. KCC2 immunoreactivity was present on the cell membrane of SPN neurons, and the normalized fluorescence intensity of KCC2 in ChAT-positive SPN neurons was decreased in SCI-vehicle group, vs. SI-vehicle group, but recovered in SCI-CLP290 group.

CONCLUSION

These results suggest that activation of KCC2 chloride ion transporter may be a therapeutic modality for the treatment of SCI-induced DO by targeting bladder efferent pathways.